Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Oncology Prices $3.2M Public Offering

NEW YORK — Predictive Oncology on Wednesday announced that it has priced a public offering of approximately 6.3 million shares of common stock at $.50 per share for gross proceeds of up to roughly $3.2 million.

Dawson James Securities and Paulson Investment Company are acting as exclusive placement agents for the offering. 

Predictive Oncology — formerly Precision Therapeutics — said it will use the proceeds of the offering for working capital, general corporate purposes, and repaying outstanding debt. It recently reported having $69,557 in cash and cash equivalents as of the end of June.

During Thursday morning trading on the Nasdaq, shares of the Eagan, Minnesota-based company were down nearly 11 percent to $.50.

Predictive Oncology operates through three subsidiaries: Helomics, which was fully acquired in 2018 and provides tumor-analysis services for treatment personalization and new drug development; TumorGenesis, which is developing patient-derived tumor models for precision drug testing; and Skyline Medical, which markets a US Food and Drug Administration-approved system for automated medical fluid disposal.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.